Absorption and disposition of a new antiarrhythmic agent bidisomide in man.
Absorption and disposition of bidisomide were studied in 12 healthy male subjects after a 20-min iv (1 mg/kg; N = 6) infusion and oral (2 mg/kg; N = 6) administration of the 14C-labeled drug. The oral absorption profile of unlabeled bidisomide was also studied after administration of a solution by a nasoenteric tube to different sites of the gastrointestinal tract (stomach, duodenum, jejunum, and ileum). The systemic availability was 61%. Absorption was slow initially and then rapid, achieving peak plasma concentrations between 2 and 4 hr. Less than complete systemic availability was attributed to incomplete absorption rather than first-pass metabolism. When the drug solution was delivered directly to the stomach, two distinct peak plasma levels were found. This was attributed to the more rapid absorption of bidisomide in the duodenum and ileum (and/or possibly colon). Following an iv dose, plasma levels of the drug declined with mean half-lives of 0.11, 2.0, and 12 hr for alpha, beta, and gamma phases, respectively, and a plasma clearance of 380 mL/min. The percentages of the dose recovered as bidisomide in urine and feces were 19 +/- 1 and 29 +/- 4 for the iv dose and 9.1 +/- 0.9 and 48 +/- 5 for the oral dose. Bidisomide did not exhibit substantial enantioselective pharmacokinetics in plasma regardless of the route of administration. The mean urinary excretion of the (-) enantiomer was, however, slightly higher than that of the (+) enantiomer, with (-)/(+) enantiomeric ratios of 1.2 and 1.3 after iv and oral administration, respectively. The enantiomeric ratio of bidisomide recovered in the feces was approximately 1.
Cook
C S
CS
Department of Drug Metabolism, Searle Research and Development, Skokie, Illinois 60077.
Ames
G B
GB
Smith
M E
ME
Kowalski
K G
KG
Karim
A
A
D000042:Absorption; D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics*; D004912:Erythrocytes / Q000378:metabolism; D006801:Humans; D008297:Male; D010880:Piperidines / Q000493:pharmacokinetics*; D012463:Saliva / Q000378:metabolism; D013237:Stereoisomerism
D000889:Anti-Arrhythmia Agents; D010880:Piperidines; C061991:bidisomide